Evidence map›Paper›PMID 32678289›Full record

ArticleLeukemia2020

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.

Disha Malani, Bhagwan Yadav, Ashwini Kumar, Swapnil Potdar, Mika Kontro, Matti Kankainen, Komal K Javarappa, Kimmo Porkka, Maija Wolf, Tero Aittokallio and 4 more

Open access · greenAbstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 4 countries.

Disha MalaniInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. disha.malani@helsinki.fi.ORCID http://orcid.org/0000-0001-9614-3281
Bhagwan YadavInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Ashwini KumarInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Swapnil PotdarInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-2778-6918
Mika KontroInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Matti KankainenHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Komal K JavarappaInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Kimmo PorkkaHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Maija WolfInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Tero AittokallioInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Krister WennerbergInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Caroline A HeckmanInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Astrid MurumägiInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Olli KallioniemiInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-3231-0332
University of Helsinki · FIOslo University Hospital · NOUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBiomarkers, TumorDasatinibDrug Resistance, NeoplasmHumansLeukemia, Myeloid, AcutePrognosisProtein Kinase InhibitorsProto-Oncogene Proteins c-kitSignal TransductionAntineoplastic AgentsBiomarkers, TumorDasatinibKIT protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-kit

Identifiers

PMID32678289
OpenAlexW3042225370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.